Press Release February 20, 2018

RA Pharmaceuticals Closes $58 Million Public Offering of Common Stock

The Life Sciences team advised RA Pharmaceuticals on its public offering totaling approximately $58 million in gross proceeds from the sale of 9,660,000 shares of common stock at a price of $6.00 per share.

RA Pharmaceuticals will use the net proceeds from the offering to fund its Phase 2 trial for RA101495 for gMG, other pipeline programs, and for working capital and general corporate purposes.

Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases.

The Goodwin team was led by partner Robert Puopolo and included associates James Xu, Yan Xing, Jessica Craig and Alexander Varond.

For more information on the offering, please read the press release.